Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neu
Document Type
Article
Publication Title
Gynecologic oncology
Abstract
INTRODUCTION: Uterine serous carcinoma (USC) is an aggressive variant of endometrial cancer with a poor prognosis. Approximately 30% of USC overexpress HER2/neu, a recognized target for trastuzumab in advanced/recurrent HER2/neu-positive USC. We evaluated the efficacy of the pan-c-erb inhibitor neratinib and the poly (ADP-ribose)-polymerase (PARP) inhibitor olaparib as single agents and in combination against USC cell lines and xenografts. METHODS: In-vitro cell-viability assays with olaparib, neratinib, and olaparib/neratinib were assessed using flow-cytometry based assays against a panel of USC cell lines with high and low HER2/neu expression. Homologous recombination deficiency (HRD) signatures were evaluated as described by Alexandrov et al. (Nature;2020;578:94-101) while downstream signaling affected by neratinib/olaparib exposure was assessed with immunoblotting. Efficacy of single- versus dual-agent inhibition was evaluated in-vivo using two USC-xenografts with 3+ HER2/neu expression. RESULTS: Neratinib was more potent than olaparib in suppression of in-vitro growth of HER2/neu 3+ cell lines (ARK1: p = 0.0047; ARK2: p = 0.0428) while no difference was noted against HER2/neu 1+ tumors (ARK4). Importantly, the combination of olaparib with neratinib synergistically improved tumor suppression compared to either single-agent in vitro. USC cells exposed to olaparib upregulated HER2/neu expression, while neratinib treatment increased PARP activity (ARK1: p < 0.0001; ARK2: p < 0.0001). Single-agent neratinib transiently inhibited in vivo growth of USC xenografts harboring HER2/neu gene amplification (ARK1: p < 0.05; ARK2: p < 0.05). In contrast, the combination of the two inhibitors caused a stronger and durable growth inhibition in both USC xenografts (ARK1: p < 0.05; ARK2: p < 0.05). CONCLUSION: The combination of olaparib and neratinib is active and synergistic against primary HER2/neu + USC. This combination may represent a novel therapeutic option for USC patients with HER2/neu+, homologous recombination-proficient tumors resistant to chemotherapy.
First Page
351
Last Page
357
DOI
10.1016/j.ygyno.2022.05.021
Publication Date
8-1-2022
Recommended Citation
Yadav, Ghanshyam; Roque, Dana M.; Bellone, Stefania; Manavella, Diego D.; Hartwich, Tobias M.; Zipponi, Margherita; Harold, Justin; Tymon-Rosario, Joan; Mutlu, Levent; Altwerger, Gary; Menderes, Gulden; Ratner, Elena; Buza, Natalia; Hui, Pei; Huang, Gloria S.; Andikyan, Vaagn; Clark, Mitchell; Azodi, Masoud; Schwartz, Peter E.; Alexandrov, Ludmil B.; and Santin, Alessandro D., "Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neu" (2022). Obstetrics and Gynecology. 184.
https://scholar.bridgeporthospital.org/obgyn/184
Identifier
35641325 (pubmed); 10.1016/j.ygyno.2022.05.021 (doi); S0090-8258(22)00332-8 (pii)